Leveraged & Inverse Content Hub Extra Bullish on Healthcare? Consider Leverage, the CURE ETF By Ben HernandezAugust 2, 2021
Innovative ETFs Content Hub A Biotech ETF to Track Nasdaq’s Industry-Setting Benchmark By Max ChenJune 30, 2021
Innovative ETFs Content Hub The Biotech Trek: A Short History from 1993 to 2021 By Max ChenJune 29, 2021
Innovative ETFs Content Hub Healthcare Services ETFs Could Continue to Rally By Max ChenJune 24, 2021
Innovative ETFs Content Hub Spice Up Your Healthcare Exposure with Some Momentum By Ben HernandezJune 22, 2021
Modern Alpha Content Hub The BioRevolution: An ETF That Taps Into Nearly Everything By Max ChenJune 21, 2021
Thematic Investing Content Hub How to Invest in a Breakout Healthcare Industry in China By Ben HernandezJune 10, 2021
Innovative ETFs Content Hub Greater Regulatory Scrutiny Could Weigh on Biotech ETFs By Max ChenMarch 24, 2021
Innovative ETFs Content Hub Illumina Earnings, Forward Guidance Strengthen Biotech ETFs By Max ChenFebruary 12, 2021
Innovative ETFs Content Hub Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug By Max ChenJanuary 29, 2021
Disruptive Technology Content Hub Targeted ETF Strategies to Capture Technological Breakthroughs By Max ChenJanuary 27, 2021
Thematic Investing Content Hub China + Healthcare = A Winning Formula for ‘CHIH’ By Ben HernandezJanuary 25, 2021
